openPR Logo
Press release

Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares

12-09-2019 06:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on December 23, 2019 in the lawsuit for certain investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

A Deadline is coming up on December 23, 2019 in the lawsuit for certain investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

A deadline is coming up on December 23, 2019 in the lawsuit filed for certain investors of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) over alleged securities laws violations by Zynerba Pharmaceuticals, Inc.

Investors who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and there are strict and short deadlines running. Deadline: December 23, 2019. NASDAQ: ZYNE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) common shares between March 11, 2019, and September 17, 2019, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between March 11, 2019, and September 17, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial, that the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares here

News-ID: 1877317 • Views: 243

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Green Dot Corporation (NYSE: GDOT)
An investor, who purchased shares of Green Dot Corporation (NYSE: GDOT), filed a lawsuit over alleged Securities Laws violations by Green Dot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Green Dot Corporation (NYSE: GDOT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 17, 2020. NYSE: GDOT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics. Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over
Deadline coming up on Jan. 20th in Lawsuit filed for Investors in shares of Cano …
A deadline is coming up on January 20, 2020 in the lawsuit filed for certain investors of Canopy Growth Corporation (NYSE: CGC) over alleged securities laws violations by Canopy Growth Corporation. Investors who purchased shares of Canopy Growth Corporation (NYSE: CGC) have certain options and there are strict and short deadlines running. Deadline: January 20, 2020. NYSE: CGC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for Investors in NYSE: LTHM shares announced over potential Securi …
Livent Corporation is under investigation concerning potential securities laws in connection with certain financial statements. Investors who purchased shares of Livent Corporation (NYSE: LTHM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Livent Corporation (NYSE: LTHM) concerning whether a series of statements by Livent Corporation

All 5 Releases


More Releases for Zynerba

Fibromyalgia Drugs Market Size, Status, Executive Summary, Regional Analysis, Ou …
The global market status for Fibromyalgia Drugs Market is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Fibromyalgia Drugs Market” Size, Status and Forecast 2019-2025, which tends to deliver in-depth knowledge associated to the Fibromyalgia Drugs Market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market
Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | GW …
Cannabinoid is a type of alkaloid that is obtained from the cannabis sativaplants. Cannabis, also known as marijuana, produce resin containing compounds known as cannabinoids. Cannabinoids are being used for medical purposes from the ancient times. These are the active substance in Cannabis plants that produce pharmacological actions in the body that mostly involves central nervous system and immune system. Delta-9-THC (tetrahydrocannabinol) is the main active component of cannabinoids. Download the
Global Fragile X Syndrome Market 2027: Top Key Players Marinus pharmaceuticals, …
Fragile X syndrome is a hereditary condition that causes a range of neurological problems including cognitive impairment and learning disabilities. Males are more affected compare to females by this disorder. It causes delayed development of speech and language by age 2. Affected children may develop attention deficit disorder; about one-third individual may develop autism, and in about 15% of male and 5% of female seizure occurs. Most males and about
Dravet Syndrome Market Forecast Analysis 2019-2023: Key Major Players are Zogeni …
MarketReportsOnline.com adds "Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023)" report to its research store. Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a severe kind of epilepsy which causes seizures. High fever is usually a trigger for these seizures. It is a rare disorder that affects an estimated 1 in every 20,000–40,000 births. It usually develops in the six month of age. It is caused
Pain Management Drugs Market Outlook to 2023 - AstraZeneca, Endo International, …
Pain management, pain medicine, pain control or algiatry, is a branch of medicine employing an interdisciplinary approach for easing the suffering and improving the quality of life of those living with chronic pain. Top players: AstraZeneca, Endo International, Johnson& Johnson, Pfizer, Purdue Pharma, Baxter, Bayer, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Eli Lilly, Zynerba Pharmaceuticals et al. For Short Sample click on: https://www.researchreportsinc.com/sample-request?id=104218 The typical pain management team includes medical practitioners, pharmacists, clinical
Needle-Free Drug Delivery Technologies 2018 Global Market Key Players – BioVal …
Needle-Free Drug Delivery Technologies Market 2018 Wiseguyreports.Com Adds “Needle-Free Drug Delivery Technologies – Global Market Growth, Opportunities, Analysis of Top Key Players and Forecast to 2023” To Its Research Database. Description: The Needle-Free Drug Delivery Technologies market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023. Based on the Needle-Free Drug Delivery